Argon plasma coagulation with atezolizumab and chemoradiation in lung pleomorphic cancer showed a remarkable response: Case report. Issue 21 (28th May 2021)

• Record Type: Journal Article
• Authors: Harada, Masanori; Morikawa, Keisuke; Kagoo, Namio; Ito, Yutaro; Kubota, Tsutomu; Ichijo, Koshiro; Mochizuki, Eisuke; Uehara, Masahiro; Matsuura, Shun; Yasuda, Kazuyo; Tsukui, Masaru; Koshimizu, Naoki
• Other Names: Saranathan. Maya section editor.
• Is Part Of: Medicine. Volume 100:Issue 21(2021)
• Publication Date: 2021-05-28
• Subjects: chemoradiotherapy -- immune checkpoint inhibitor -- lung pleomorphic carcinoma -- radiofrequency -- synergistic effect; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000026149
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale: Lung pleomorphic carcinoma (LPC) is generally resistant to chemotherapy or radiotherapy. However, a combination of immune checkpoint inhibitors and radiotherapy has a remarkable efficacy against LPC. Patient Concerns and Diagnoses: Here, we report the case of a 50-year old man diagnosed with progressive LPC. The tumor invaded the carina and predominantly obstructed the right main bronchus; therefore, a combination of palliative chemoradiotherapy and atezolizumab was initiated. However the trachea was gradually obstructed. Intervention and Outcome: Argon plasma coagulation (APC) was performed to prevent tumor invasion. After three APC sessions, the tumor showed a necrotic change and was easily excised using biopsy forceps. Lessons: A combination of chemoradiotherapy, atezolizumab, and APC showed a good efficacy, and the patient had a good response to atezolizumab maintenance therapy. Multidisciplinary treatments, such as a combination of immune checkpoint inhibitors and APC, could have synergistic efficacy in lung cancer.